AAM Moves to Block Connecticut's New Drug Price Law
The Association for Accessible Medicines (AAM) has filed for a federal injunction to prevent Connecticut from enforcing a new price-control law.
The law, which took effect in July, is set to start regulating prices in January 2026. AAM argues that it threatens patient access to low-cost drugs and violates the US Constitution.
- The statute allegedly gives Connecticut illegal authority to control drug prices across state lines.
- It unfairly targets generic and biosimilar manufacturers rather than branded drugmakers.
- AAM contends that the law will reduce competition, raise costs, and drive some generics from the market.
Generics currently account for around 90% of all prescriptions but only 12% of drug spending, while branded products represent the bulk of healthcare costs.
AAM filed the request on October 23 in the US District Court for the District of Connecticut.
Author's summary: AAM files for federal injunction against Connecticut's drug price law.
More News
- Babar Azam, Mohammad Rizwan in focus: PCB clears Big Bash NOCs for Pakistan players, but with a catch
- No quick fix for ‘tiresome’ M50 gridlock, Minister says
- Canada's Air Transat to suspend flights
- Commuters hot under the collar as snow, ice gridlock roads across Seoul
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Benin authorities say coup attempt foiled, President Talon safe
- Benin coup attempt foiled by loyalist troops, interior minister says
- Gridlocked Halloween, 2025, @kaltgatzke flashbang film. I ...
- Congress gridlocked on key issues as year-end deadline looms